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A B S T R A C T
AIDS-related lymphomas (ARL) present high biological heterogeneity. For better 
characterization of this type of lymphoma, the objectives of the present study were to 
evaluate the expression of immunohistochemical markers of cell differentiation (CD10, 
Bcl-6, MUM-1) and determine cell origin profile according to Hans’ classification of diffuse 
large B-cell lymphoma in AIDS patients. This study included 72 consecutive patients with 
ARL diagnosed at the University Hospital, Universidade Federal do Rio de Janeiro (UFRJ) and 
at the Brazilian Instituto Nacional de Câncer (INCA) from 2000 to 2006. The morphologic 
distribution of the lymphomas was the following: 61% were diffuse large B-cell lymphomas 
(DLBCLs), 15% were Burkitt’s lymphomas, 13% were plasmablastic lymphomas, 10% 
were high-grade lymphomas and 1% was follicular lymphoma. The positivity for each 
immunohistochemical marker in DLBCLs, Burkitt’s lymphoma and plasmablastic 
lymphoma was respectively: CD20, 84%, 100%, and 0; CD10, 55%, 100%, and 0; Bcl-6, 45%, 
80%, and 0; MUM-1, 41%, 20%, and 88%. A higher positivity of CD20 (84% x 56%, p = 0.01) 
was found in DLBCL compared to non-DLBCL; in Burkitt’s lymphomas a higher positivity 
of CD10 (100% x 49%, p = 0.04) and Bcl-6 (80% x 39%, p = 0.035) were found compared to 
non-Burkitt’s lymphomas. Germinal center (GC) profile was detected in 60% of DLBCLs. 
Our study suggests particular findings in ARL, as the most frequent phenotype was GC, 
different from HIV-negative patients. 
immunohistochemical markers of cell differentiation (CD10, 
Bcl-6 and MUM1) can be used to determine the GC and non-GC 
subtypes of DLBCL, and predict survival similar to the cDNA 
microarray.4
Few studies have reported the use of immunohistochemical 
expression of CD10, Bcl-6, and/or MUM1 to classify cases of 
DLBCL into GC and non-GC subtypes in ARL patients.5-7 In two 
studies, a higher prevalence rate of GC subtypes was found.5,6 
Also, co-expression of GC and activation markers was noted in 
ARL when compared to lymphomas in HIV-negative patients.8
Introduction
Non-Hodgkin lymphoma is the second most common 
malignancy in HIV-infected patients and is an AIDS-defining 
condition. Diffuse large B-cell lymphoma (DLBCL) is the 
most common subtype of AIDS-related lymphoma (ARL).1,2
Data from gene expression studies have indicated that 
markers of germinal center (GC) derivation are associated with 
clinical behavior in DLBCL in immunocompetent patients.3 
Further work led to the confirmation that the expression of 
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The aim of the present study was to evaluate the expression 
of immunohistochemical markers of cell differentiation (CD10, 
Bcl-6, MUM-1) and to determine the cell origin profile according 
to Hans’ classification of DLBCL in AIDS patients.
Methods
This study included 72 consecutive patients with AIDS-related 
lymphoma treated on initial diagnosis at the Brazilian Instituto 
Nacional de Câncer (INCA) and at the Hospital of Universidade 
Federal do Rio de Janeiro from 2000 to 2006. Diagnosis of DLBCL, 
Burkitt’s lymphoma, plasmablastic lymphoma and high-grade 
lymphoma were confirmed independently on review by two authors 
(DA and JCM) using morphologic and immunohistochemical 
criteria defined in the WHO classification.9 The diagnosis of 
“unclassifiable B-cell lymphoma”, with intermediate features 
between DLBCL and Burkitt lymphoma LBCL and BL was not 
possible, because molecular analysis was not available. The same 
pathologists analyzed the immunohistochemical tissue sections.
Patients were selected based on the availability of 
histological material for tissue microarray (TMA) construction. 
The following baseline clinical characteristics were recorded: 
sex, age, stage, presence of bulky disease or B symptoms, 
performance status and blood counts. The international 
prognostic index (IPI) was computed; patients were categorized 
as low risk IPI if they presented with up to two risk factors; and as 
high risk IPI if three or more risk factors were present.10 The 
study was approved by the institutions’ Ethics Committees.
Tissue microarrays (TMA) were constructed using a tissue 
arrayer (Beecher Instruments, Silver Spring, MD). Duplicated cores 
of 1.0 mm were selected from areas of characteristic morphology 
typical of the case, based on examination of the hematoxylin 
and eosin-stained original whole tissue sections, without prior 
knowledge of immunohistologic stains of individual cases. These 
areas were circled on the glass slide of the whole section and 
superimposed on the corresponding paraffin block, which was 
then punched at the selected location to obtain the desired core. 
4 mm–thick sections were cut from the TMA and placed on glass 
slides, which were then baked for 1 hour at 60ºC. These slides 
were then subjected to immunohistochemistry. 
Monoclonal antibodies to the following antigens 
were used: CD10 (56C6; Novocastra, dilution 1:900- 
Novolink amplification), Bcl-6 (PG-B6p; DAKO; dilution 1: 
Antigens    DLBCL       BL       PL      HGL     Total
 % (n/total) % (n/total) % (n/total) % (n/total) % (n/total)
CD20 84 (37/44) 100 (11/11) 0 (0/9) 57 (4/7) 74 (53/72)
CD10 55 (24/44) 100 (10/10) 0 (0/9) 71 (5/7) 56 (40/71)
Bcl-6 45 (19/42) 80 (8/10) 0 (0/9) 57 (4/7) 45 (31/69)
MUM-1 41 (17/42) 20 (2/10) 88 (7/8) 29 (2/7) 41 (28/68)
BL, Burkitt´s lymphoma; PL, plasmablastic lymphoma; HGL, high grade lymphoma; Total, including one follicular lymphoma; % number of 
cases with positive immunomarkers/number of available cases for analysis.
Table 1 - Immunophenotypic analysis per morphologic group
350-Novolink amplification), MUM-1 (MUM1p; DAKO; 
dilution 1:8000-Novolink amplification), CD20 (L26; 
DAKO; dilution 1:1500-Novolink amplification).
Cases were interpreted as positive when more than 30% of 
neoplastic cells were immunoreactive.
Cases were assigned to the GC group if CD10 alone was 
positive, or if both Bcl-6 and CD10 were positive. If both Bcl-6 
and CD10 were negative, the case was assigned to the non-
GCB subgroup. If Bcl-6 was positive and CD10 was negative, 
the expression of MUM1 determined the group: if MUM1 was 
negative, the case was assigned to the GCB group; if MUM1 
was positive, the case was assigned to the non-GCB group.4
Results
The median age of the patients was 40 years (range: 8-69 
years), and 52 (72%) were men. Patients’ main characteristics 
at diagnosis were: the presence of B symptoms in 74% (25/34); 
bulky disease in 72% (18/25), extranodal disease in 53% (9/17), 
advanced disease (Ann Arbor stage III or IV) in 61% (27/44) and 
high IPI in 34% (13/38).
A total of 44 patients (61%) were classified as DLBCL, 11 (15%) 
were Burkitt’s lymphomas, 9 (13%) were plasmablastic lymphomas 
and 7 (10%) were high grade lymphomas. One patient had the 
diagnosis of follicular lymphoma in the morphologic review.
The distribution of markers (described in Table 1) in DLBCLs, 
Burkitt’s lymphoma and plasmablastic lymphoma are CD20: 
84%, 100%, and 0; CD10: 55%, 100%, and 0; Bcl-6: 45%, 80%, 
and 0; MUM-1: 41%, 20%, and 88%. A higher positivity of 
CD20 (84% x 56%, p = 0.01) was found in DLBCL compared 
to non-DLBCL; in Burkitt’s lymphomas there were higher 
CD10 (100% x 49%, p = 0.04) and Bcl-6 (80% x 39%, p = 0.035) 
positivity rates compared to non-Burkitt’s lymphomas 
(Table 1).
Among DLBCL patients, cell origin assignment was verified 
using Hans’ definitions.4 In one case, the subtype could not be 
determined. GC profile was detected in 60% (26/43) and non-GC 
profile in 40% (17/43).
Among cases in which the expression of all three antigens 
(CD10, BCL-6, and MUM-1) was successfully evaluated 
(42 patients) – positive examples are shown on Figs. 1, 2 and 
3 – we compared the distribution of the various combinations 
with the reported data (Table 2).4,6
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DLBCL  CD10 BCL-6  MUM1   % positive 
Present study
     % positive 
Chadburn’s series
  % positive 
 Hans’ series
GC + - - 2 4 3
GC - + - 5 2 14
GC + + - 31 27 18
GC + - + 12 2 1
GC + + + 10 19 6
NGC - - + 19 23 21
NGC - + + 0 17 18
NGC - - - 21 6 19
Table 2 - Results in different series of GC profile following Hans’ algorithm
Fig. 1 - CD10 (x 400) – membranous immunoreactivity to 
anti-CD10 antibody in 100% of the tumor cells.
Fig. 2 - Bcl-6 (x 400) – nuclear immunoreactivity to  
anti-Bcl6 antibody in 70% of the tumor cells.
Fig. 3 - MUM-1 (x 400) – nuclear  immunoreactivity to  
anti-MUM1 antibody in 90% of the neoplastic cells.
Discussion
The present study was designed to determine the cell origin 
profile according to Hans’ classification in AIDS-related 
DLBCL. Higher prevalence of GC profile was observed (60%). 
This finding is in accordance with results of other series of 
HIV-infected patients.6,7 In a series of HIV-negative patients 
in the same institution, during a similar period, only 38% had 
the GC profile.11 It has been postulated that antigenic B-cell 
stimulation in the context of relatively preserved immune 
function, typical of the HAART era, could disproportionately 
promote germinal center pathways of lymphomagenesis.7 Our 
results highlight the biological differences in the origin of the 
lymphoma in HIV-infected patients.
Previous studies have described high rates of co-expression 
of GC antigens and activation markers in HIV associated 
lymphomas.6,8 This might represent a final stage of intra-GC 
differentiation in ARL, suggesting a unique pathophysiology. 
Our results are in line with this observation and show CD10 
and MUM-1 co-expression more prevalent than in HIV-negative 
series (12% x 1%).4 In other series of HIV-infected patients, this 
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phenomenon was verified with a higher Bcl-6 and MUM-1 
co-expression, not seen in our series.6 This low Bcl-6 and 
MUM-1 co-expression may be related to the difficulties in 
reproducing Bcl-6 results usually reported.6,12
Regarding other main characteristics, we found ARL 
subtype distribution similar to previous studies, with 61% of 
DLBCL (74% if plasmablastic lymphoma included) and 16% 
of Burkitt’s lymphoma. DLBCL accounts for 70-80% of systemic 
AIDS-related lymphomas in most reports, including the largest 
Brazilian one.13-15 In concordance with these series, our 
patients had a median age of 40 years, were male, presented 
with higher prevalence of extranodal disease at diagnosis 
and high or high-intermediate IPI.14,15
In conclusion, the present study found AIDS-related DLBCL 
to be mostly of GC profile, different from the findings in 
HIV-negative series.
Acknowledgements
We thank José Ivanildo Neves and Carlos Ferreira do 
Nascimento, from Hospital do Cancer AC Camargo, for the 
TMA construction.
Conflict of interest
All authors declare to have no conflict of interest.
R E F E R E N C E S 
 1. Tirelli U, Spina M, Gaidano G, et al. Epidemiological, 
biological and clinical features of HIV-related lymphomas 
in the era of highly active antiretroviral therapy. AIDS. 
2000;14:1675-88.
 2. Gucalp A, Noy A. Spectrum of HIV lymphomas 2009. Curr 
Opin Hematol. 2010;17(4):362-7.
 3. Alizadeth AA, Eisen MB, Davis RE, et al. Distinct types of 
diffuse large B-cell lymphoma identified by gene expression 
profiling. Nature. 2000;403:503-11.
 4. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of 
the molecular classification of diffuse large B-cell lymphoma 
by immunohistochemistry using a tissue microarray. Blood. 
2004;103:275-82.
 5. Hoffmann C, Tiemann M, Schrader C, et al. AIDS-related 
B cell lymphoma (ARL): correlation of prognosis with 
differentiation profiles assessed by immunophenotyping. 
Blood. 2005;106:1762-9.
 6. Chadburn A, Chiu A, Lee JY, et al. Immunophenotypic analysis 
of AIDS-related diffuse large B-cell lymphoma and clinical 
implications in patients from AIDS Malignancies Consortium 
Clinical Trials 010 and 034. J Clin Oncol. 2009;30:5039-48.
 7. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment 
of acquired immunodeficiency syndrome-related lymphoma 
with dose-adjusted EPOCH: impact of antiretroviral therapy 
suspension and tumor biology. Blood. 2003;101:2653-9.
 8. Madan R, Gormley R, Dalau A, et al. AIDS and non-AIDS 
diffuse large cell lymphomas expressdifferent antigen 
profiles. Mod Pathol. 2006;19:438-46.
 9. Swerlow SH, Campo E, Harris NL, et al. WHO Classification 
of Tumors of Haematopoietic and Lymphoid Tissue (4th ed). 
Lyon, France: IARC Press; 2008.
10. A predictive model for aggressive non-Hodgkins lymphoma. 
The International Non-Hodgkins Lymphoma Prognostic 
Factors Project. N Engl J Med. 1993;329:987-94.
11. Camara D, Stefanoff S, Pires A, et al. Immunoblastic 
morphology in diffuse large B-cell lymphoma with a 
non-germinal center immunophenotypic profille. Leuk 
Lymphoma. 2007;48(5):892-6.
12. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical 
methods for predicting cell of origin and survival in patients 
with Diffuse large B-cell lymphoma treated with Rituximab.  
J Clin Oncol. 2011;29(2):200-7.
13. Stebbing J, Gazzard B, Mandalia S, et al. Antiretroviral 
treatment regimens and immune parameters in the 
prevention of systemic AIDS-related non-Hodgkin´s 
lymphoma. J Clin Oncol. 2004;22(11):2177-83.
14. Tanaka PY, Pracchia LF, Calore EE, et al. Non-Hodgkin´s 
lymphoma among patients infected with human 
immunodeficiency virus: the experience of a single center in 
Brazil. Int J Hematol. 2006;84:337-42. 
15. Tanaka PY, Pracchia LF, Bellosso M, et al. A prognostic score 
for AIDS-related diffuse large B-cell lymphoma in Brazil. Ann 
Hematol. 2010;89:45-51.
